4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp.

4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp.

Neisseria meningitidis serogroup B (MenB) is the leading cause of meningococcal meningitis and sepsis in industrialized countries, with the highest incidence in infants and adolescents. Two recombinant protein vaccines that protect against MenB are now available (i.e. 4CMenB and MenB-fHbp). Both vac...

Full description

Bibliographic Details
Main Authors: Daniele Veggi, Federica Bianchi, Laura Santini, Paola Lo Surdo, Chelsy C Chesterman, Werner Pansegrau, Nicoletta Bechi, Ying Huang, Vega Masignani, Mariagrazia Pizza, Rino Rappuoli, Matthew J Bottomley, Roberta Cozzi, Domenico Maione
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-10-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1008882

Internet

https://doi.org/10.1371/journal.ppat.1008882

Similar Items